4.3 Review

Neurological symptoms and blood neurofilament light levels

期刊

ACTA NEUROLOGICA SCANDINAVICA
卷 144, 期 1, 页码 13-20

出版社

WILEY
DOI: 10.1111/ane.13415

关键词

biomarker; neurofilament; neurologic disease

资金

  1. Swiss National Science Foundation [P400PM_191077]
  2. Swedish Research Council [2018--02532]
  3. European Research Council [681712]
  4. Swedish State Support for Clinical Research [ALFGBG--720931]
  5. Alzheimer Drug Discovery Foundation (ADDF), USA [201809--2016862]
  6. UK Dementia Research Institute at UCL
  7. MRC [UKDRI-1003] Funding Source: UKRI
  8. Swiss National Science Foundation (SNF) [P400PM_191077] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

NfL serves as a specific marker for neuronal injury, but lacks specificity for the cause or location of the damage, potentially indicating disease activity in neurological conditions. The utility of NfL in different diseases has been reviewed, revealing its universal nature as a marker of neuronal damage that extends beyond individual diseases, with potential benefits from considering the relationship between neurological symptoms and blood NfL levels.
Neurofilament light chain (NfL) is an incredibly specific marker of neuronal injury that is not specific for cause or location of the neuronal damage. NfL is increasingly considered as possible biomarker of disease activity in neurological conditions. Several works reviewed the utility of NfL in the different diseases. Nonetheless, NfL is a universal marker of neuronal damage, which interpretation spaces beyond the single disease. Because of this, the interpretation of NfL may benefit by also considering how neurological symptoms relate to its blood concentration. Here, we review how different neurological symptoms can be associated with blood NfL levels with a practical interpretation of it.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据